Greg Wolf to Immunotherapy
This is a "connection" page, showing publications Greg Wolf has written about Immunotherapy.
Connection Strength
0.966
-
Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, McHugh JB. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol. 2020 12; 111:104928.
Score: 0.589
-
Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011 Dec; 33(12):1666-74.
Score: 0.305
-
Liu S, Bellile E, Nguyen A, Zarins K, D'Silva N, Rozek L, Wolf GT, Sartor MA. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncol. 2021 12; 123:105587.
Score: 0.040
-
Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, N?r JE, Ferris RL, Wolf GT, Sun D, Lei YL. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clin Cancer Res. 2018 09 01; 24(17):4242-4255.
Score: 0.032